Sector | Healthcare | Compare with Sector peers |
Industry | Hospital & Healthcare Services | Compare with Industry peers |
Website | http://www.lalpathlabs.com | |
Market Cap | 19,341.40 Cr. | |
Enterprise Value(EV) | 18,680.00 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 39.52 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 58.63 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 66.39 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 222.14 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 10.43 | Calculated using Price: 2,316.95 |
Dividend Yield | 0.52 | Period Ending 2023-03 |
No. of Shares Subscribed | 8.35 Cr. | 83,477,852 Shares |
FaceValue | 10 | |
About Dr. Lal Pathlabs Ltd. | ||
The company is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Its customers include individual patients, hospitals and other healthcare providers and corporate customers. |
1 Day |
|
-1.43% |
1 Week |
|
-0.65% |
1 Month |
|
+1.81% |
3 Month |
|
-5.47% |
6 Month |
|
-6.06% |
1 Year |
|
+18.38% |
2 Year |
|
-7.02% |
5 Year |
|
+116.96% |
10 Year |
|
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 37.14 | 32.45 | 28.45 | 25.32 | 23.76 | 23.74 | 26.89 | 26.45 | 15.8 | |
Return on Capital Employed (%) | 48.87 | 47.43 | 43.07 | 37.9 | 34.78 | 32.94 | 36.03 | 32.67 | 20.34 | |
Return on Assets (%) | 24.67 | 25.06 | 24.13 | 21.81 | 20.38 | 18.81 | 19.87 | 17.77 | 10.36 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 341 | 507 | 596 | 788 | 946 | 1,033 | 1,245 | 1,502 | 1,666 | 1,772 | |
Non Curr. Liab. | -5 | 12 | -6 | -9 | -20 | 70 | 83 | 273 | 176 | 122 | |
Curr. Liab. | 112 | 91 | 85 | 116 | 138 | 227 | 274 | 500 | 470 | 471 | |
Minority Int. | 2 | 3 | 2 | 4 | 5 | 21 | 31 | 35 | 33 | 34 | |
Equity & Liab. | 450 | 613 | 676 | 899 | 1,069 | 1,351 | 1,633 | 2,310 | 2,345 | 2,399 | |
Non Curr. Assets | 168 | 189 | 210 | 276 | 255 | 459 | 488 | 1,435 | 1,372 | 1,320 | |
Curr. Assets | 282 | 424 | 467 | 623 | 814 | 893 | 1,145 | 875 | 973 | 1,079 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 450 | 613 | 676 | 899 | 1,069 | 1,351 | 1,633 | 2,310 | 2,345 | 2,399 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 660 | 791 | 912 | 1,057 | 1,203 | 1,330 | 1,581 | 2,087 | 2,017 | 2,172 | |
Other Income | 13 | 22 | 28 | 31 | 46 | 55 | 51 | 53 | 42 | 65 | |
Total Income | 673 | 813 | 940 | 1,088 | 1,249 | 1,385 | 1,633 | 2,140 | 2,059 | 2,237 | |
Total Expenditure | -504 | -584 | -675 | -793 | -910 | -987 | -1,145 | -1,527 | -1,527 | -1,592 | |
PBIDT | 168 | 229 | 265 | 295 | 340 | 399 | 488 | 613 | 532 | 645 | |
Interest | 0 | -1 | -1 | -1 | -1 | -15 | -16 | -30 | -38 | -32 | |
Depreciation | -28 | -28 | -28 | -33 | -38 | -73 | -77 | -108 | -150 | -145 | |
Taxation | -43 | -67 | -81 | -90 | -100 | -83 | -98 | -125 | -103 | -135 | |
Exceptional Items | |||||||||||
PAT | 96 | 133 | 156 | 172 | 200 | 228 | 296 | 350 | 241 | 333 | |
Minority Interest | -1 | -1 | -1 | -1 | -1 | -2 | -5 | -5 | -2 | -4 | |
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 96 | 132 | 155 | 171 | 199 | 226 | 292 | 345 | 239 | 330 | |
Adjusted EPS | 17 | 16 | 19 | 20 | 24 | 27 | 35 | 41 | 29 | 40 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 98 | 122 | 159 | 171 | 197 | 219 | 284 | 398 | 447 | 456 | |
Cash Fr. Inv. | -90 | -113 | -163 | -137 | -172 | -100 | -26 | -212 | -449 | -287 | |
Cash Fr. Finan. | -10 | -1 | 0 | -32 | 13 | -55 | -190 | -139 | 136 | -283 | |
Net Change | -2 | 8 | -5 | 2 | 37 | 64 | 67 | 48 | 134 | -114 | |
Cash & Cash Eqvt | 16 | 23 | 19 | 29 | 66 | 129 | 197 | 244 | 378 | 264 |
Fri, 03 May 2024
Board Meeting Intimation for Consideration And Approval Of The Audited (Standalone & Consolidated) Financial Results Of The Company For The Quarter And Financial Year Ended March 31 2024 And To Consider Recommending Final Dividend If Any Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2024 inter alia to consider and approve the Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Financial year ended March 31 2024 and to consider recommending Final Dividend if any |
Fri, 03 May 2024
Compliances-Reg.24(A)-Annual Secretarial Compliance Certificate attached for financial year ended March 31 2024 |
Fri, 03 May 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find attached the invite of the Conference Call for Investors/ Analysts to be held on Friday May 10 2024 at 03.30 P.M. (IST) to discuss the financialand operating performance for Q4 & FY24. |
Fri, 03 May 2024 |
Closing Below Previous Low |
Closing Below Previous Low for 2 Days |
Making Lower Lows for 2 Days |
High Increase in 5 Years |
CCI Bearish |